Studies on the mechanisms underlying these phenomena have shown that celastrol inhibits the expression of GLUT1, HK2, and LDH, and reduces the activity of HK and LDH, thereby inhibiting glycolysis in gastric cancer cells (Li K. et al., 2019). Here, SLC2A1 is linked to gastric cancer.